2024年9月，Journal of Dementia and Alzheimer's Disease (JDAD) 、Therapeutics 正式创刊上线。欢迎各位专家学者关注，了解更多新刊信息。

 

 

 

/ 期刊简介 /

 

 

JDAD (ISSN 3042-4518) 是一个国际性、同行评审的开放获取期刊。此期刊涵盖所有类型的痴呆症，重点是阿尔茨海默病和记忆研究。欢迎关注疾病发生和进展的分子和细胞方面的生物学研究，以及临床研究踊跃投稿。

 

/ 期刊主编 /

Prof. Dr. Magda Tsolaki
Chair of Greek Federation of Alzheimer's Disease, Greece;
Aristotle University of Thessaloniki, Greece

 

研究兴趣：痴呆；阿尔茨海默病；神经心理学；生物标志物；非药物干预；面向患者和护理人员的新技术；新冠肺炎后神经系统并发症。

 

/更快发表速度 /
 

Time to First Decision	16 Days
Acceptance to Publication	5.8 Days

 

/ 精选文章 /

1. Tiny Carriers, Tremendous Hope: Nanomedicine in the Fight against Parkinson's
微小载体，巨大希望：纳米医学对抗帕金森病
Nitu Dogra, Ruchi Jakhmola Mani and Deepshikha Pande Katare
https://www.mdpi.com/2840784

 

原文出自 JDAD 期刊
Dogra, N.; Jakhmola Mani, R.; Pande Katare, D. Tiny Carriers, Tremendous Hope: Nanomedicine in the Fight against Parkinson’s. J. Dement. Alzheimer's Dis. 2024, 1, 3-21.

2. Unraveling Alzheimer's: Exploring the Gut Microbiota–Brain Axis as a New Frontier in Understanding
揭秘阿尔茨海默病：探索肠道微生物-脑轴作为理解的新前沿
Shahzada Mudasir Rashid et al.
https://www.mdpi.com/2840960

 

原文出自 JDAD 期刊
Rashid, S.M.; Razak, R.; Tantray, A.K.; James, A.W.; Showkat, N.; Shehjar, F.; Jan, F.; Ahmad, S.B.; Khan, A.; Shah, Z.A. Unraveling Alzheimer’s: Exploring the Gut Microbiota–Brain Axis as a New Frontier in Understanding. J. Dement. Alzheimer's Dis. 2024, 1, 22-47.

3. Information Recognition and Recall in Older Adults Bearing Vascular Risk Factors with or without Diagnosis of Mild Cognitive Impairment
有血管危险因素伴或不伴轻度认知障碍诊断的老年人的信息识别和回忆
Glykeria Tsentidou et al.
https://www.mdpi.com/2966716

 

原文出自 JDAD 期刊
Tsentidou, G.; Moraitou, D.; Masoura, E.; Metallidou, P.; Papadopoulos, E.; Papaliagkas, V.; Tsolaki, M. Information Recognition and Recall in Older Adults Bearing Vascular Risk Factors with or without Diagnosis of Mild Cognitive Impairment. J. Dement. Alzheimer's Dis. 2024, 1, 72-86.

/ 精选特刊 /

Novel Therapies for Neurodegenerative Disorders
Submissions Deadline: 30 November 2024
Edited by Dr. Zahoor Shah and Dr. Faheem Shehjar
https://www.mdpi.com/si/195595

 

 

 

 

/ 期刊简介 /

 

 

Therapeutics (ISSN 2813-9909) 是一个关于现代和传统治疗技术的国际开放获取期刊。Therapeutics 专注于发表关于预防和治疗人类疾病的前沿研究。我们鼓励科学家尽可能详细地发表他们的实验和理论结果，包括可能被认为是“负面”的结果。欢迎具有原创性的研究和综述踊跃投稿。

/ 期刊主编 /

Prof. Dr. Nejat Duzguneş
University of the Pacific, USA

 

研究兴趣：基因治疗 (口腔癌)、光动力疗法 (口腔癌)、噬菌体治疗 (分枝杆菌感染)、根除艾滋病毒 (通过自杀基因疗法)、纳米医学。

/更快发表速度 /
 

Time to First Decision	16 Days
Acceptance to Publication	5.8 Days

 

/ 精选文章 /

1. Synergistic Antitumor Effects of ¹⁷⁷Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model
¹⁷⁷Lu -奥曲肽联合ALK抑制剂在高危神经母细胞瘤异种移植模型中的协同抗肿瘤作用
Arman Romiani et al.
https://www.mdpi.com/2903462

 

原文出自 Therapeutics 期刊
Romiani, A.; Pettersson, D.; Rassol, N.; Simonsson, K.; Bakr, H.; Lind, D.E.; Kovács, A.; Spetz, J.; Palmer, R.H.; Hallberg, B.; et al. Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model. Therapeutics 2024, 1, 4-21.

2. Safety and Efficacy of Primary EUS-Guided Choledochoduodenostomy for Malignant Distal Biliary Obstruction: A Systematic Review and Meta-Analysis
内镜超声引导下胆总管十二指肠吻合术治疗恶性胆道远端梗阻的安全性和有效性：系统回顾和meta分析
Eugene Annor et al.
https://www.mdpi.com/2908752

 

原文出自 Therapeutics 期刊
Annor, E.; Gopakumar, H.; Vohra, I.; Puli, S.R. Safety and Efficacy of Primary EUS-Guided Choledochoduodenostomy for Malignant Distal Biliary Obstruction: A Systematic Review and Meta-Analysis. Therapeutics 2024, 1, 22-33.

3. Continued Anticomplement Therapy: A Lifeline for Post-Renal-Transplant Patients with Complement-Mediated Hemolytic Uremic Syndrome
持续抗补体治疗：补体介导的溶血性尿毒症综合征肾移植后患者的生命线
Natasha Venugopal et al.
https://www.mdpi.com/2950992

 

原文出自 Therapeutics 期刊
Venugopal, N.; Polimera, H.V.; Santucci, J.; Washburn, E.; Federici, E. Continued Anticomplement Therapy: A Lifeline for Post-Renal-Transplant Patients with Complement-Mediated Hemolytic Uremic Syndrome. Therapeutics 2024, 1, 34-41.

/ 精选特刊 /

Skin Disease and Inflammation: Current Treatment and Future Options
Submissions Deadline: 31 March 2025
Edited by Dr. Annunziata Dattola
https://www.mdpi.com/si/211899